Wuhan Kefu New Drug Co., Ltd.

Primary objective: To evaluate the safety and tolerability of TXA-070 tablets in healthy adult trial participants. Secondary objective: To evaluate the pharmacokinetic characteristics of TXA-070 tablets after single and multiple doses in healthy adult trial participants.

1. To evaluate the safety of 0.5% TML-023 ointment administered twice daily in patients with proliferative superficial infantile hemangiomas. 2. To evaluate the efficacy of 0.5% TML-023 ointment, administered twice daily, in treating proliferative superficial infantile hemangiomas by assessing the cure rate (independent evaluation) at the end of treatment or at each follow-up visit (6 weeks, 12 weeks, 18 weeks, 24 weeks, 36 weeks, and 52 weeks). The cure rate was defined as the proportion of trial participants who achieved complete or near-complete regression.

Primary objective: To evaluate the safety and tolerability of a single oral dose of different LS21031 capsules in healthy participants. Secondary objective: To evaluate the pharmacokinetic characteristics of the parent compound and metabolites of LS21031 after a single oral dose in healthy participants.